Get startedLog in
    Picture of Novakand Pharma AB logo

    NOVKAN — Novakand Pharma AB News Story

    0.000.00%
    se flag iconLast trade - 00:00
    HealthcareHighly SpeculativeMicro CapSucker Stock
    All News

    Brief: Kancera Gets Positive FDA Feedback On Clinical Development Program For Kand567

    Picture of Novakand Pharma AB logoNovakand Pharma AB
    05/06/2025 07:08
    June 5 (Reuters) - Kancera AB KANC.ST:

RECEIVED POSITIVE FDA FEEDBACK ON PLANNED CLINICAL DEVELOPMENT PROGRAM FOR KAND567 IN ST-ELEVATION MYOCARDIAL INFARCTION

PROPOSED CLINICAL DEVELOPMENT PLAN COULD SUPPORT MARKETING APPLICATION, BE ELIGIBLE FOR FAST TRACK DESIGNATION

Source text: ID:nMFN4tjbwB

Further company coverage: KANC.ST

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))

    Recent news on Novakand Pharma AB

    See all news